Aspirin/omeprazole 325/40

Drug Profile

Aspirin/omeprazole 325/40

Alternative Names: Aspirin enteric-coated (EC)/omeprazole immediate-release (IR) 325/40; Omeprazole/aspirin 40mg/325mg; PA 032540; PA 325; PA 32540; Yosprala 325/40

Latest Information Update: 27 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator POZEN
  • Developer Aralez Pharmaceuticals Inc.
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiplatelets; Antipyretics; Antirheumatics; Antiulcers; Benzimidazoles; Gastric antisecretories; Non-opioid analgesics; Salicylates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cardiovascular disorders

Most Recent Events

  • 04 Apr 2018 Aralez Pharmaceuticals announces intention to discontinue the sales of Aspirin/omeprazole (Yosprala®) in USA in 2018
  • 11 Jan 2017 Aralez Pharmaceuticals has patent protection for aspirin/omeprazole 325/40 in USA
  • 03 Oct 2016 Launched for Cardiovascular disorders (Prevention of relapse) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top